Publications

LEO Pharma employees were authors or co-authors on the following publications published between 2014 and 2016.

2016

Ma L, Yang Q, Yang H, Wang G, Zheng M, Hao F, Gu J, Sun Q, Cui P, Ge M, Li R, Gao T, Facy P, Kurvits M, Xu Z, Xu J.
Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population.
International journal of dermatology. 2016; 55(1): 106-113.
DOI: 10.1111/ijd.12788
PMID: 26094549

Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K.
A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.
Journal of cutaneous medicine and surgery. 2016; 20(1): 44-51.
DOI: 10.1177/1203475415597094
PMID: 26224733

Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Olesen M, Lowson D, Yamauchi P.
Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study.
The Journal of Clinical and Aesthetic Dermatology. 2016;9(2):34-41.
PMCID: PMC4771388
PMID: 27313822

Sinnya S, Tan JM, Prow TW, Primiero C, McEniery E, Selmer J, Østerdal ML, Soyer HP.
A randomised, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis.
The British journal of dermatology. 2016 Feb; 174(2): 305-311.
DOI:
10.1111/bjd.14245
PMID: 26499175

Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J.
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study.
The Journal of dermatological treatment. 2016; 27(2): 120-127.
DOI: 10.3109/09546634.2015.1083935
PMID: 26444907

Lovato P, Norsgaard H, Tokura Y, Røpke MA.
Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
Journal of Dermatological Science. 2016 Mar;81(3):153-64.
DOI: 10.1016/j.jdermsci.2015.12.009
PMID: 26794805

Frederiksen K, Guy RH, Petersson K.
The potential of polymeric film-forming systems as sustained delivery platforms for topical drugs.
Expert opinion on drug delivery. 2016; 13(3): 349-360.
DOI: 10.1517/17425247.2016.1124412
PMID: 26609868

Garbe C, Basset-Seguin N, Poulin Y, Larsson T, Østerdal ML, Venkata R, Lear JT.
Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomised controlled 12-month study.
The British journal of dermatology. 2016; 174(3) 505-513.
DOI: 10.1111/bjd.14222
PMID: 26471889

Asche CV, Zografos P, Norlin JM, Urbanek B, Mamay C, Makin C, Erntoft S,  Chen CC, Hines DM,   Siegel DM.
Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the US.
Value in Health, 2016 Mar-Apr;19(2):239-48.
DOI:10.1016/j.jval.2015.11.014
PMID: 27021759

Feldman SR, Møller AH, Idemyr STE, González JM.
Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
Journal of Health Economics and Outcomes Research. 2016; 4(2):141-57.

Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H.
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
The European journal of health economics : HEPAC : health economics in prevention and care. 2016; 17(3): 287-304.
DOI: 10.1007/s10198-015-0679-8
PMID: 25795391

Kawamura S, Chu H, Felding J, Baran PS.
Nineteen-step total synthesis of (+)-phorbol.
Nature. 2016 Apr 7;532(7597):90-3. 
DOI:10.1038/nature17153
PMID: 27007853

Ritzén A, Sørensen MD, Dack KN, Greve DR, Jerre A, Carnerup MA, Rytved KA, Bagger-Bahnsen J.
Fragment-Based Discovery of 6-Arynlindazole JAK Inhibitors.
ACS Medicinal Chemistry Letters. 2016 Apr 14;7(6):641-6.
DOI: 10.1021/acsmedchemlett.6b00087
PMID: 27326341

Erntoft S, Norlin JM, Pollard C, Diepgen TL.
Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study.
British Journal of Dermatology. 2016 Apr 18. [Epub ahead of print]
DOI: 10.1111/bjd.14680
PMID: 27088541

Le TT, Skak K, Schroder K, Schroder WA, Boyle GM, Pierce CJ, Suhrbier A.
IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.
PLoS One. 2016 Apr 21;11(4):e0153975.
DOI: 10.1371/journal.pone.0153975
PMID: 27100888

Foley P, Stockfleth E, Peris K, Basset-Seguin N, Cerio R, Antonio Sanches J, Guillen C, Farrington E, Lebwohl M.
Adherence to topical therapies in actinic keratosis: A literature review.
Journal of Dermatological Treatment. 2016 May 10:1-8. [Epub ahead of print]
DOI: 10.1080/09546634.2016.1178372
PMID: 27161045

Iversen L, Jakobsen HB.
Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict.
Dermatology and Therapy. 2016 Jun;6(2):273-85
DOI: 10.1007/s13555-016-0119-4
PMID: 27125383

Queille-Roussel C, Bang B, Clonier F, Lacour JP.
Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.
Journal of European Academy of Dermatology and Venereology. 2016 Jun 15.
DOI: 10.1111/jdv.13714
PMID: 27306589

Ernst M, Saslis-Lagoudakis CH, Grace OM, Nilsson N, Simonsen HT, Horn JW, Rønsted N.
Evolutionary prediction of medicinal properties in the genus Euphorbia L.
Scientific Reports: 2016 Jul 28;6:30531.

Stein Gold L, Lebwohl M, Menter A, Villumsen J, Rosen M, Koo J.
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Journal of Drugs in Dermatology. 2016 Aug 1;15(8):951-7.
PMID: 27537995

Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Moller A, Osterdal ML, Stein Gold L.
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Journal of Drugs and Dermatology. 2016 Aug 1;15(8):981-7.
PMID: 27537999

Bertelsen M, Stahlhut M, Grue-Sørensen G, Liang X, Christensen GB, Skak K, Engell KM, Högberg T.
Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers.
Dermatology and Therapy. 2016 Aug 8. [Epub ahead of print]
DOI: 10.1007/s13555-016-0137-2
PMID: 27503482

Ulrich M, Reinhold U, Skov T, Søndergaard RE, Guitera P.
Histological examination confirms clinical clearance of AKs following treatment with ingenol mebutate 0.05% gel.
British Journal of Dermatology. 2016 Aug 12. [Epub ahead of print]
DOI: 10.1111/bjd.14968
PMID: 27518593

Paul C, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Bang B, Griffiths CE.
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
Journal of European Academy of Dermatology and Venereology. 2016 Aug 17 [Epub ahead of print].
DOI: 10.1111/jdv.13859
PMID: 27531752

Jim On SC, Knudsen KM, Skov T, Lebwohl M.
Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel.
Clinical, Cosmetic and Investigational Dermatology. 2016 Aug 24;9:211-6.
DOI: 10.2147/CCID.S113044
PMID: 27601928

Pedersen CB, McHorney CA, Larsen LS, Lophaven KW, Moeller AH, Reaney M.
Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris.
Journal of Dermatological Treatment. 2016 Sep 5:1-8. [Epub ahead of print]
DOI: 10.1080/09546634.2016.1215405
PMID: 27454156

Lind M, Nielsen KT, Schefe LH, Nørremark K, Eriksson AH, Norsgaard H, Pedersen BT, Petersson K.
Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients.
Dermatology and Therapy. 2016 Sep;6(3):413-25.
DOI: 10.1007/s13555-016-0125-6
PMID: 27358072

Emmert S, Haenssle HA, Zibert JR, Schön M, Hald A, Hansen MH, Litman T, Schön MP.
Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.
PloS One. 2016 Sep 9;11(9):e0160096
DOI: 10.1371/journal.pone.0160096
PMID: 27612149

Björklund S, Pham QD, Jensen LB, Knudsen NØ, Nielsen LD, Ekelund K, Ruzgas T, Engblom J, Sparr E.
The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier.
Journal of Colloid and Interface Science. 2016 Oct 1;479:207-20.
DOI: 10.1016/j.jcis.2016.06.054
PMID: 27388135

Stein Gold L, Villumsen J, Rosen M.
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis.
Dermatology and Therapy. 2016 Oct 6. [Epub ahead of print]
DOI: 10.1007/s13555-016-0147-0
PMID: 27714595

Hanke WC, Norlin JM, Mark Knudsen K, Larsson T, Stone S.
Quality of life in treatment of AK: Treatment burden of ingenol mebutate gel is small and short lasting.
Journal of Dermatological Treatment. 2016 Oct;27(5):450-5.
DOI: 10.3109/09546634.2016.1160024
PMID: 27052110

2015

Augustin M, Tu JH, Knudsen KM, Erntoft S, Larsson T, Hanke W.
Ingenol Mebutate Gel for Actinic Keratosis: The Link Between Quality of Life, Treatment Satisfaction, and Clinical Outcomes  (TSQM).
Journal of the American Academy of Dermatology. 2015 May;72(5):816-21.
DOI: 10.1016/j.jaad.2015.01.036
PMID: 25770879

Ernst M, Grace OM, Saslis-Lagoudakis CH, Nilsson N, Simonsen HT, Rønsted N.

Global medicinal uses of Euphorbia L. (Euphorbiaceae).
Journal of Ethnopharmacology. 2015 Dec 24;176:90-101.
DOI: 10.1016/j.jep.2015.10.025
PMID: 26485050

Nilsson N, Felding J.
Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.
Future medicinal chemistry. 2015; 7(14): 1853-1859.
DOI: 10.4155/fmc.15.122
PMID: 26393392

Garvie-Cook H, Frederiksen K, Petersson K, Guy RH, Gordeev S.
Characterization of topical film-forming systems using atomic force microscopy and Raman microspectroscopy.
Molecular pharmaceutics. 2015; 12(3): 751-757.
DOI: 10.1021/mp500582j
PMID: 25586343

Renata H, Zhou Q, Dünstl G, Felding J, Merchant RR, Yeh CH, Baran PS.
Development of a concise synthesis of ouabagenin and hydroxylated corticosteroid analogues.
Journal of the American Chemical Society. 2015; 137(3): 1330-1340.
DOI: 10.1021/ja512022r
PMID: 25594682

Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, Estrada YD, Peng X, Mitsui H, Litman T, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E.
Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection.
The Journal of allergy and clinical immunology. 2015; 135(1): 153-163.
DOI: 10.1016/j.jaci.2014.10.037
PMID: 25567045

Løvendorf MB, Mitsui H, Zibert JR, Røpke MA, Hafner M, Dyring-Andersen B, Bonefeld CM, Krueger JG, Skov L.
Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis.
Experimental dermatology. 2015; 24(3): 187-193.
DOI: 10.1111/exd.12604
PMID: 25431026

Queille-Roussel C, Olesen M, Villumsen J, Lacour JP.
Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
Clinical drug investigation. 2015; 35(4): 239-245.
DOI: 10.1007/s40261-015-0269-7
PMID: 25708531

Frederiksen K, Guy RH, Petersson K.
Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2015; 91: 9-15.
DOI: 10.1016/j.ejpb.2015.01.002
PMID: 25595740

Costantini VJ, Corsi M, Dünstl G, Bettelini L, Zonzini L, Gerrard P.
The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Experimental dermatology. 2015; 24(4): 312-314.
DOI: 10.1111/exd.12656
PMID: 25650546

Soini EJ, Hallinen T, Sokka AL, Saarinen K.
Cost-utility of first-line actinic keratosis treatments in Finland.
Advances in therapy. 2015; 32(5): 455-476.
DOI: 10.1007/s12325-015-0211-7
PMID: 26006101

Stockfleth E, Peris K, Guillen C, Cerio R, Basset-Seguin N, Foley P, Sanches J, Culshaw A, Erntoft S, Lebwohl M.
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis.
International journal of dermatology. 2015; 54(5): 509-515.
DOI: 10.1111/ijd.12840
PMID: 25865875

Nielsen MM, Dyring-Andersen B, Schmidt JD, Witherden D, Lovato P, Woetmann A, Ødum N, Poulsen SS, Havran WL, Geisler C, Bonefeld CM.
NKG2D-dependent activation of dendritic epidermal T cells in contact hypersensitivity.
The Journal of investigative dermatology. 2015; 135(5): 1311-1319.
DOI: 10.1038/jid.2015.23
PMID: 25634359

Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, Hædersdal M.
Health related quality of life in patients with actinic keratosis--an observational study of patients treated in dermatology specialist care in Denmark.
Health and quality of life outcomes. 2015; 13:111.
DOI: 10.1186/s12955-015-0295-4
PMID: 26220553

Møller AH, Erntoft S, Vinding GR, Jemec GB.
A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values.
Patient related outcome measures. 2015; 6: 167-177.
DOI: 10.2147/PROM.S81428
PMID: 26185476

Garvie-Cook H, Frederiksen K, Petersson K, Guy RH, Gordeev SN.
Biophysical elucidation of the mechanism of enhanced drug release and topical delivery from polymeric film-forming systems.
Journal of controlled release : official journal of the Controlled Release Society. 2015; 212: 103-112.
DOI: 10.1016/j.jconrel.2015.06.015
PMID: 26087467

Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators.
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
JAMA. 2015; 314(7): 677-686.
DOI: 10.1001/jama.2015.9243
PMID: 26284719

Norlin JM, Malmberg I, Synnerstad I, Tennvall GR.
Treatment Patterns and Cost of Actinic Keratosis During 12 Months – A Swedish Register-based Study.
Forum for Nordic Dermato-Venereology. 2015; 20(1): 4-9.

Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF.
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.
Molecular cancer therapeutics. 2015; 14(9): 2132-2142.
DOI: 10.1158/1535-7163.MCT-15-0023-T
PMID: 26116359

Lambert J, Hol CW, Vink J.
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Journal of the European Academy of Dermatology and Venereology. 2015; 29(12): 2349-2355.
DOI: 10.1111/jdv.13230
PMID: 26337069

Jin Y, Yeh CH, Kuttruff CA, Jørgensen L, Dünstl G, Felding J, Natarajan SR, Baran PS.
C-H Oxidation of Ingenanes Enables Potent and Selective Protein Kinase C Isoform Activation.
Angewandte Chemie (International ed. in English). 2015; 54(47): 14044-14048.
DOI: 10.1002/anie.201507977
PMID: 26418078

Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G.
Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology.
Haematologica. 2015; 100(11): 1486-1492.
DOI: 10.3324/haematol.2015.127126
PMID: 26294737

Pellacani G, Peris K, Guillen C, Clonier F, Larsson T, Venkata R, Puig S.
A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body.
Journal of the European Academy of Dermatology and Venereology. 2015; 29(11): 2192-2198.
DOI: 10.1111/jdv.13211
PMID: 26300464

Rasmussen G, Bech LL, Nielsen TW.
An Applicator Delivery System for Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Topical Suspension (Gel): Innovating Psoriasis Vulgaris Treatment Through Patient Collaboration.
Dermatology and therapy. 2015; 5(4): 235-246.
DOI: 10.1007/s13555-015-0087-0
PMID: 26541164

Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Osterdal ML, Stein Gold L.
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris - a Randomized Phase III Study (PSO-FAST).
Journal of drugs in dermatology. 2015; 14(12): 1468-1477.
PMID: 26659941



2014

Willis M, Erntoft S, Persson S, Norlin JM, Persson U.
Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting.
Journal of health economics and outcomes research. 2014; 2(1): 1-14.

Berman B, Goldenberg G, Hanke CW, Tyring SK, Werschler WP, Knudsen KM, Goncalves J, Larsson T, Skov T, Swanson N.
Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Journal of drugs in dermatology. 2014; 13(2): 154-160.
PMID: 24509965

Berman B, Goldenberg G, Hanke CW, Tyring SK, Werschler WP, Knudsen KM, Larsson T, Swanson N.
Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Journal of drugs in dermatology. 2014; 13(6): 741-747.
PMID: 24918567

Gooderham M, Debarre JM, Keddy-Grant J, Xu Z, Kurvits M, Goodfield M.
Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age.
The British journal of dermatology. 2014; 171(6): 1470-1477.
DOI: 10.1111/bjd.13235
PMID: 24980277

Løvendorf MB, Zibert JR, Gyldenløve M, Røpke MA, Skov L.
MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis.
Journal of dermatological science. 2014; 75(2): 133-139.
DOI: 10.1016/j.jdermsci.2014.05.005
PMID: 24909097


Queille-Roussel C, Clonier F, Olesen M.
Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach.
The British journal of dermatology. 2014; 171(6): 1596-1598.
DOI: 10.1111/bjd.13328
PMID: 25109395


Anderson L, Jarratt M, Schmieder G, Shumack S, Katsamas J, Welburn P.
Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm2 on the Forearm(s) of Patients with Actinic Keratosis.
The Journal of Clinical and Aesthetic Dermatology. 2014; 7(12): 19-29.
PMID: 25584134

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.